The early impacts of primary HPV cervical screening implementation in Australia on the pathology sector: a qualitative study

• Κύριοι συγγραφείς: Claire Bavor (Συγγραφέας), Julia ML Brotherton (Συγγραφέας), Megan A Smith (Συγγραφέας), Khic-Houy Prang (Συγγραφέας), Tracey McDermott (Συγγραφέας), Nicole M Rankin (Συγγραφέας), Claire M Zammit (Συγγραφέας), Chloe J Jennett (Συγγραφέας), Farhana Sultana (Συγγραφέας), Dorothy A Machalek (Συγγραφέας), Claire E Nightingale (Συγγραφέας), on behalf of the STORIES team (Συγγραφέας)
• Μορφή: Βιβλίο
• Έκδοση: BMC, 2023-10-01T00:00:00Z.
• Θέματα: article
• Διαθέσιμο Online: Connect to this object online.
• Notes: 10.1186/s12913-023-10040-6; 1472-6963
• Keywords: Cervical screening; Cervical cancer; Pathology; HPV; Implementation; Qualitative; Public aspects of medicine; RA1-1270
• Source: BMC Health Services Research, Vol 23, Iss 1, Pp 1-11 (2023)

Abstract Background The transition of Australia's National Cervical Screening Program from cytology to a molecular test for human papillomavirus (HPV) (locally referred to as the 'Renewal'), including a longer five-year interval and older age at commencement, significantly impacted all sectors of program delivery. The Renewal had major implications for the roles and requirements of pathology laboratories providing services for the Program. This study aimed to understand the early impacts of the Renewal and its implementation on the pathology sector. Methods Semi-structured qualitative interviews were conducted with key stakeholders (N = 49) involved in the STakeholder Opinions of Renewal Implementation and Experiences Study (STORIES), 11-20 months after the program transition. A subset of interviews (N = 24) that discussed the pathology sector were analysed using inductive thematic analysis. Results Four overarching themes were identified: implementation enablers, challenges, missed opportunities, and possible improvements. Participants believed that the decision to transition to primary HPV screening was highly acceptable and evidence-based, but faced challenges due to impacts on laboratory infrastructure, resources, staffing, and finances. These challenges were compounded by unfamiliarity with new information technology (IT) systems and the new National Cancer Screening Register ('Register') not being fully functional by the date of the program transition. The limited availability of self-collection and lack of standardised fields in pathology forms were identified as missed opportunities to improve equity in the Program. To improve implementation processes, participants suggested increased pathology sector involvement in planning was needed, along with more timely and transparent communication from the Government, and clearer clinical management guidelines. Conclusion The transition to primary HPV screening had a significant and multifaceted impact on the Australian pathology sector reflecting the magnitude and complexity of the Renewal. Strategies to support the pathology sector through effective change management, clear, timely, and transparent communication, as well as adequate funding sources will be critical for other countries planning to transition cervical screening programs.